Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

Although sorafenib is currently used as a standard treatment for advanced hepatocellular carcinoma, low response rate, transient and limited efficacy, primary and acquired resistance and negative side-effects gain increasing attentions, suggesting the need for better efficacious combination therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Junjie, Zheng, Longbo, Chen, Jiang, Sun, Yin, Lin, Hui, Jin, Ren-an, Tang, Minyue, Liang, Xiao, Cai, Xiujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680567/
https://www.ncbi.nlm.nih.gov/pubmed/29022906
http://dx.doi.org/10.1038/cddis.2017.411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680567/
https://www.ncbi.nlm.nih.gov/pubmed/29022906
http://dx.doi.org/10.1038/cddis.2017.411

Ejemplares similares